Potential interaction between warfarin and fluvastatin

Annals of Pharmacotherapy

Volumn 30, Issue 12, 1996, Pages 1399-1401

  Trilli, Lauren E ^a,b   Kelley, Catherine L ^a,b   Aspinall, Sherrie L ^a,b   Kroner, Beverly A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; CORONARY ARTERY DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030460426     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001207     Document Type: Article

References (13)

1. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865-75.
2. Wells PS, Holbrook AM, Crowther MR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
3. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995;52:1639-45.
4. Tse FLS, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993;82:942-7.
5. Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P 450 TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995;58:412-7.
6. Package insert. Lescol (fluvastatin sodium). East Hanover, NJ: Sandoz Pharmaceuticals Corp., December 1993.
7. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin. IV. Identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
8. Brian WB, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990;29:11,280-92.
9. Ahmad S. Lovastatin:warfarin interaction. Arch Intern Med 1990;150:2407.
10. Hoffman HS. The interaction of lovastatin and warfarin (letter). Conn Med 1992;56:107.
11. Walker JF. Simvastatin: the clinical profile. Am J Med 1989;87(suppl 4A):44S-6S.
12. Pan HY. HMG-CoA reductase inhibitors: clinical pharmacology. In: Gotto AM Jr, Mancini M, Richter WO, eds. Treatment of severe hypercholesterolemia in prevention of coronary heart disease. 2. Proceedings of the Second International Symposium, Munich 1989. Basel: Karger, 1990:66-70.
13. Jungnickel PW, Cantral KA, Maloley PA. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharm 1992;11:677-89.